Fabtech Technologies bags Multi million dollar projects from Syria, Germany

Image
Announcement Corporate
Last Updated : Jan 21 2013 | 6:21 AM IST

Fabtech Technologies International Pvt Ltd, the company providing complete manufacturing solutions has bagged two very prestigious multi million dollar biotech turnkey construction projects in Syria and Germany. In August this year, Fabtech won a Rs 25 crore project from the numero uno company in Syria, Asia Pharmaceuticals Industries. Two months later, it again grabbed a similar Rs 20 crore project from Action Medeor, Germany.

Fabtech has been awarded the Syrian project on turnkey basis which includes conceptual design, basic engineering, detailed engineering, supply of fill finish machines, sterile vessels with magnetic stirrers , transfer piping with complete automation right from charging, filtration and holding to the filling buffer tank, programmed cip system to work without any manual intervention, laminar flow units flushed to the ceiling, autoclaves, inner walls in sandwich modular clean room paneling system , heating ventilation and air-conditioning with complete building management system automation for temperature, relative humidity and pressure. The scope also includes complete utility piping for purified water, water for injection, pure steam, compressed air, nitrogen storage and distribution system along with Installation, validation and commissioning the entire plant. 

Asia Pharmaceutical Industries (API) is one of the pioneering distinctive pharmaceutical companies in Syria and the Middle East which produces about 300 pharmaceutical products. Its product range includes pharmaceutical generic categories like hormones, sterile injectables and recently the biotech products starting with insulin. All products are designed as accurately optimised facilities that conform to the current norms specified by the international regulatory agencies, namely, the US FDA, Modern Humanities Research Association (MHRA) of UK (and consequently EU), Therapeutic Goods Administration (TGA) of Australia, etc.

Germany-based Medical Aid Organisation, Action Medeor handed over its Tanzanian project on a turnkey basis to Fabtech among six international bidders for Design, Planning, Supply and Execution of a Solid Dosage Pharmaceutical Plant in Arusha, Tanzania.  Action Medeor, established in 1964  is the largest medical aid charitable, non-governmental organisation in Europe. It provides basic drugs and medical equipment to people in developing countries. Action Medeor is also involved in fighting the poverty-related and tropical diseases HIV/Aids, tuberculosis and malaria, particularly in Africa. The scope of work  for the pharma unit in Tanzania includes the entire gamut of work – from complete interior works to HVAC supply and installation to production equipment to service, maintenance and environmental safeguards and warranty.

Aasif Khan, Director, Fabtech Technologies International Pvt Ltd says, "Fabtech Technologies is committed to providing total solutions in the area of pharmaceutical & biotechnology facility design and  execution. We have been designing and constructing sophisticated clean rooms for pharma companies for several years. The Syrian project is another feather in our cap. The Syrian project  is for a formulation facility for 5 filling and packing lines which are completely segregated to facilitate filling of multi products at one time"

Fabtech Technologies International is in the business of manufacturing innovative products for the pharmaceutical sector, with internationally acclaimed and certified technology. With an array of products to choose from and an extensive marketing reach, Fabtech has made its presence felt in India and now the middle east markets.

About Fabtech Technologies International Pvt
Fabtech Technologies International Pvt .Ltd. designs and builds Pharmaceutical & Biotech facilities internationally. In its 14 years of existence, Fabtech has executed more than 75 projects spread across 20 countries. Fabtech has built an excellent infrastructure to manufacture pre-fabricated & pre-engineered modular panels (inner construction), Isolation & Containment solutions and clean air equipment including Sterilizing Tunnels which it supplies in the Indian and international market.

Fabtech is a leading player in the Indian Cleanrooms market for modular panels and doors with a market share of about 25%. Already active in the Middle East, Persian Gulf and Africa and Afro Arab countries, with certification from Warrington Fire, Fabtech has forged alliances in North America, Europe, Latin America & South Africa to make a footprint in these territories. With Bio safety labs, Modular Prefab Pre engineering internal walls, and Isolation systems,  Fabtech aims to be ‘a Specialist construction company’. For this, Fabtech aspires to get into the outer box (external construction) segment.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 01 2010 | 7:25 PM IST

Next Story